Free Trial

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

CollPlant Biotechnologies logo
$1.43 +0.02 (+1.70%)
As of 07/11/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

Key Stats

Today's Range
$1.38
$1.46
50-Day Range
$1.35
$4.54
52-Week Range
$1.31
$5.45
Volume
62,691 shs
Average Volume
35,672 shs
Market Capitalization
$18.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

CollPlant Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

CLGN MarketRank™: 

CollPlant Biotechnologies scored higher than 59% of companies evaluated by MarketBeat, and ranked 510th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about CollPlant Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CollPlant Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CollPlant Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CollPlant Biotechnologies has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CollPlant Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    0.88% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 9.21%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CollPlant Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    CollPlant Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.88% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 9.21%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CollPlant Biotechnologies has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for CollPlant Biotechnologies this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for CLGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

  • Read more about CollPlant Biotechnologies' insider trading history.
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

CLGN Stock News Headlines

CollPlant Biotechnologies Ltd. (CLGN) - Yahoo Finance
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

CLGN Stock Analysis - Frequently Asked Questions

CollPlant Biotechnologies' stock was trading at $3.60 at the start of the year. Since then, CLGN stock has decreased by 60.0% and is now trading at $1.44.

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) released its quarterly earnings results on Wednesday, June, 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.24. The business earned $2.06 million during the quarter, compared to the consensus estimate of $9.76 million. CollPlant Biotechnologies had a negative net margin of 560.92% and a negative trailing twelve-month return on equity of 87.33%.

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

Last Earnings
6/04/2025
Today
7/12/2025
Next Earnings (Estimated)
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CLGN
CIK
1631487
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$11.00
Potential Upside/Downside
+698.6%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.61 million
Net Margins
-560.92%
Pretax Margin
-560.92%
Return on Equity
-87.33%
Return on Assets
-65.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.48
Quick Ratio
4.23

Sales & Book Value

Annual Sales
$510 thousand
Price / Sales
35.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.18 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
12,720,000
Free Float
11,495,000
Market Cap
$18.32 million
Optionable
Optionable
Beta
1.33
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CLGN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners